312 related articles for article (PubMed ID: 11312351)
1. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung.
Croyle MA; Chirmule N; Zhang Y; Wilson JM
J Virol; 2001 May; 75(10):4792-801. PubMed ID: 11312351
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver.
Croyle MA; Chirmule N; Zhang Y; Wilson JM
Hum Gene Ther; 2002 Oct; 13(15):1887-900. PubMed ID: 12396620
[TBL] [Abstract][Full Text] [Related]
3. Utility of PEGylated recombinant adeno-associated viruses for gene transfer.
Le HT; Yu QC; Wilson JM; Croyle MA
J Control Release; 2005 Nov; 108(1):161-77. PubMed ID: 16125817
[TBL] [Abstract][Full Text] [Related]
4. Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats.
Lei D; Lehmann M; Shellito JE; Nelson S; Siegling A; Volk HD; Kolls JK
Hum Gene Ther; 1996 Dec; 7(18):2273-9. PubMed ID: 8953318
[TBL] [Abstract][Full Text] [Related]
5. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
6. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy.
Moffatt S; Hays J; HogenEsch H; Mittal SK
Virology; 2000 Jun; 272(1):159-67. PubMed ID: 10873758
[TBL] [Abstract][Full Text] [Related]
7. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues.
Yang Y; Su Q; Grewal IS; Schilz R; Flavell RA; Wilson JM
J Virol; 1996 Sep; 70(9):6370-7. PubMed ID: 8709265
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration.
McClane SJ; Chirmule N; Burke CV; Raper SE
Hum Gene Ther; 1997 Dec; 8(18):2207-16. PubMed ID: 9449374
[TBL] [Abstract][Full Text] [Related]
9. Readministration of helper-dependent adenovirus to mouse lung.
Koehler DR; Martin B; Corey M; Palmer D; Ng P; Tanswell AK; Hu J
Gene Ther; 2006 May; 13(9):773-80. PubMed ID: 16437131
[TBL] [Abstract][Full Text] [Related]
10. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.
Yang Y; Li Q; Ertl HC; Wilson JM
J Virol; 1995 Apr; 69(4):2004-15. PubMed ID: 7884845
[TBL] [Abstract][Full Text] [Related]
11. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.
O'Riordan CR; Lachapelle A; Delgado C; Parkes V; Wadsworth SC; Smith AE; Francis GE
Hum Gene Ther; 1999 May; 10(8):1349-58. PubMed ID: 10365665
[TBL] [Abstract][Full Text] [Related]
12. Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype.
Sparer TE; Wynn SG; Clark DJ; Kaplan JM; Cardoza LM; Wadsworth SC; Smith AE; Gooding LR
J Virol; 1997 Mar; 71(3):2277-84. PubMed ID: 9032363
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.
Gahéry-Ségard H; Molinier-Frenkel V; Le Boulaire C; Saulnier P; Opolon P; Lengagne R; Gautier E; Le Cesne A; Zitvogel L; Venet A; Schatz C; Courtney M; Le Chevalier T; Tursz T; Guillet JG; Farace F
J Clin Invest; 1997 Nov; 100(9):2218-26. PubMed ID: 9410899
[TBL] [Abstract][Full Text] [Related]
14. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.
Yang Y; Trinchieri G; Wilson JM
Nat Med; 1995 Sep; 1(9):890-3. PubMed ID: 7585213
[TBL] [Abstract][Full Text] [Related]
15. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice.
Zsengeller ZK; Wert SE; Hull WM; Hu X; Yei S; Trapnell BC; Whitsett JA
Hum Gene Ther; 1995 Apr; 6(4):457-67. PubMed ID: 7612702
[TBL] [Abstract][Full Text] [Related]
16. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
17. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.
Mastrangeli A; Harvey BG; Yao J; Wolff G; Kovesdi I; Crystal RG; Falck-Pedersen E
Hum Gene Ther; 1996 Jan; 7(1):79-87. PubMed ID: 8825871
[TBL] [Abstract][Full Text] [Related]
18. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle.
Yang Y; Haecker SE; Su Q; Wilson JM
Hum Mol Genet; 1996 Nov; 5(11):1703-12. PubMed ID: 8922997
[TBL] [Abstract][Full Text] [Related]
19. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung.
Minter RM; Rectenwald JE; Fukuzuka K; Tannahill CL; La Face D; Tsai V; Ahmed I; Hutchins E; Moyer R; Copeland EM; Moldawer LL
J Immunol; 2000 Jan; 164(1):443-51. PubMed ID: 10605041
[TBL] [Abstract][Full Text] [Related]
20. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
